Skip to main content
. 2020 Jan 1;16(1):147–161. doi: 10.7150/ijbs.36955

Figure 6.

Figure 6

(A) Western bloting of galectin-1 in total lysates of SW620 and HCT116 cells after treated with shikonin; (B) Cell inhibition ratios in SW620 and galectin-1 overexpressed SW620 (SW620-Gal1); (C) Cell inhibition ratios in HCT116 and galectin-1 overexpressed HCT116 (SW620-Gal1); (D) Quantification of flow cytometry analysis to assess total apoptotic ratios in SW620 and SW620-Gal1 after treated with shikonin; (E) Quantification of flow cytometry analysis to assess total apoptotic ratios in HCT116 and HCT116-Gal1 after treated with shikonin; (F) Laser confocal microscopy images; (G-I) Changes in expression of Dimer-gal1, gal-1, p62, LC3 and Cyto c after treatment with si-gal1, shikonin (SK) or both; (J-K) Changes in expression of Dimer-gal1 and gal-1 after treatment with shikonin (SK), NAC or both; (L-M) Changes in expression of EMT markers after treatment with si-gal1, shikonin (SK) or both.